IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

2023.10.27
IDweek2023A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial The approval of the long-acting injectable cabotegravir-rilpivirine in January 2021 marked a significant milestone in the medical realm. This dual-drug regimen has revolutionized the approach to HIV treatment by providing an effective and convenient alternative to daily oral medications. However, the question of how to best optimize access to this therapy in our clinics was an issue that required immediate attention. Consequently, a hypothesis was developed suggesting that cabotegravir-rilpivirine could be safely and effectively administered in a person’s own home, paving the way for an innovative study to test this theory.